Kymera Therapeutics (NASDAQ: KYMR) director sells 12,000 shares under 10b5-1 plan

Q: What insider transaction did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?

Kymera reported that director Elena Ridloff exercised stock options for 12,000 common shares at $14.18 per share and sold 12,000 shares in open-market trades around $85–$86 per share, fully disposing of the exercised shares.

Q: What option terms applied to the Kymera Therapeutics (KYMR) shares exercised by Elena Ridloff?

The director exercised fully vested stock options with a $14.18 exercise price per share. These options related to 12,000 underlying common shares that were converted into stock and then sold, according to the Form 4 transaction details and accompanying footnote on vesting.

Q: At what prices did the Kymera Therapeutics (KYMR) insider sales occur?

Shares were sold in multiple trades at weighted average prices of $85.37, $85.19, and $86.05 per share. Footnotes explain each average reflects numerous trades within narrow price ranges, and detailed breakdowns are available upon request.

Q: What net effect did the Form 4 transactions have on Kymera Therapeutics (KYMR) insider ownership?

The transactions show an exercise-and-sell pattern : 12,000 shares acquired via option exercise and 12,000 shares sold. The transaction summary reports 12,000 shares exercised, 12,000 shares sold, and a net-sell direction, resulting in no directly held shares remaining from these grants.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics director Elena Ridloff exercised stock options covering 12,000 shares of common stock at an exercise price of $14.18 per share, then sold 12,000 shares in open-market transactions at weighted average prices around $85–$86 under a pre-arranged Rule 10b5-1 trading plan, leaving no directly held common shares reported.

Insider Trade Summary 10b5-1

Net Seller: 12,000 shares ($1,024,660)

Net Sell 7 txns

Insider Ridloff Elena

Role Director

Sold 12,000 shs ($1.02M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	4,600	$0.00	--
Exercise	Common Stock	4,600	$14.18	$65K
Sale	Common Stock	3,400	$85.1946	$290K
Sale	Common Stock	1,200	$86.05	$103K
Exercise	Stock Option (Right to Buy)	7,400	$0.00	--
Exercise	Common Stock	7,400	$14.18	$105K
Sale	Common Stock	7,400	$85.3701	$632K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 4,600 shares (Direct)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Options exercised: 12,000 shares at $14.18/share Shares sold: 12,000 shares Sale price (weighted avg 1): $85.3701 per share +3 more

6 metrics

Options exercised 12,000 shares at $14.18/share Stock option exercises converting into common stock

Shares sold 12,000 shares Total common shares sold across reported transactions

Sale price (weighted avg 1) $85.3701 per share Common stock open-market sale on 2026-03-31

Sale price (weighted avg 2) $85.1946 per share Common stock open-market sale on 2026-04-01

Sale price (weighted avg 3) $86.0500 per share Additional common stock sale on 2026-04-01

Post-transaction direct holdings 0 shares Total_shares_following_transaction on final reported sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

fully vested and exercisable financial

"The shares underlying this stock option are fully vested and exercisable."

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ridloff Elena

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/31/2026		M⁽¹⁾		7,400	A	$14.18	7,400	D
Common Stock	03/31/2026		S⁽¹⁾		7,400	D	$85.3701⁽²⁾	0	D
Common Stock	04/01/2026		M⁽¹⁾		4,600	A	$14.18	4,600	D
Common Stock	04/01/2026		S⁽¹⁾		3,400	D	$85.1946⁽³⁾	1,200	D
Common Stock	04/01/2026		S⁽¹⁾		1,200	D	$86.05	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.18	03/31/2026		M⁽¹⁾			7,400	⁽⁴⁾	06/15/2032	Common Stock	7,400	$0	4,600	D
Stock Option (Right to Buy)	$14.18	04/01/2026		M⁽¹⁾			4,600	⁽⁴⁾	06/15/2032	Common Stock	4,600	$0	0	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?

Kymera reported that director Elena Ridloff exercised stock options for 12,000 common shares at $14.18 per share and sold 12,000 shares in open-market trades around $85–$86 per share, fully disposing of the exercised shares.

Were Kymera Therapeutics (KYMR) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 11, 2025. Such plans pre-arrange trade timing and size, indicating the reported sales followed a preset schedule rather than discretionary market timing.

What option terms applied to the Kymera Therapeutics (KYMR) shares exercised by Elena Ridloff?

The director exercised fully vested stock options with a $14.18 exercise price per share. These options related to 12,000 underlying common shares that were converted into stock and then sold, according to the Form 4 transaction details and accompanying footnote on vesting.

At what prices did the Kymera Therapeutics (KYMR) insider sales occur?

Shares were sold in multiple trades at weighted average prices of $85.37, $85.19, and $86.05 per share. Footnotes explain each average reflects numerous trades within narrow price ranges, and detailed breakdowns are available upon request.

How many Kymera Therapeutics (KYMR) shares did the director hold after these transactions?

After the reported option exercises and sales, the Form 4 shows zero common shares directly owned in the affected line items. The total_shares_following_transaction fields for the final reported sales are listed as 0.0000, indicating no remaining directly held shares in this security class.

What net effect did the Form 4 transactions have on Kymera Therapeutics (KYMR) insider ownership?

The transactions show an exercise-and-sell pattern: 12,000 shares acquired via option exercise and 12,000 shares sold. The transaction summary reports 12,000 shares exercised, 12,000 shares sold, and a net-sell direction, resulting in no directly held shares remaining from these grants.